Repligen (RGEN) to Release Quarterly Earnings on Thursday
Repligen (NASDAQ:RGEN) is set to release its earnings data before the market opens on Thursday, February 22nd. Analysts expect Repligen to post earnings of $0.12 per share for the quarter.
Repligen (NASDAQ RGEN) opened at $32.99 on Thursday. The company has a market capitalization of $1,391.91, a price-to-earnings ratio of 55.92, a price-to-earnings-growth ratio of 1.79 and a beta of 0.91. Repligen has a one year low of $29.56 and a one year high of $46.81.
Several brokerages have recently issued reports on RGEN. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research note on Wednesday, February 7th. Zacks Investment Research raised Repligen from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. TheStreet lowered Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th. Jefferies Group reaffirmed a “hold” rating and set a $40.00 price target on shares of Repligen in a research note on Thursday, October 19th. Finally, JPMorgan Chase & Co. began coverage on Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Repligen currently has a consensus rating of “Buy” and an average target price of $44.38.
TRADEMARK VIOLATION NOTICE: “Repligen (RGEN) to Release Quarterly Earnings on Thursday” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/15/repligen-rgen-to-release-quarterly-earnings-on-thursday.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.